| Bobby Joe Wolfe Jr, | |
|
100 Tamberline St, Brandon, MS 39042-3164 | |
| (601) 825-2141 | |
| Not Available |
| Full Name | Bobby Joe Wolfe Jr |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine - Public Health & General Preventive Medicine |
| Location | 100 Tamberline St, Brandon, Mississippi |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740324698 | NPI | - | NPPES |
| 00123676 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083P0901X | Preventive Medicine - Public Health & General Preventive Medicine | 07076 (Mississippi) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Bobby Joe Wolfe Jr, 100 Tamberline St, Brandon, MS 39042-3164 Ph: (601) 825-2141 | Bobby Joe Wolfe Jr, 100 Tamberline St, Brandon, MS 39042-3164 Ph: (601) 825-2141 |
News Archive
Experts have identified new strategies for using electronic health records (EHRs) to treat patients with chronic kidney disease. These recommendations may help clinicians and hospitals better manage individual patients with chronic conditions and identify groups of patients most likely to benefit from different treatment strategies.
A review of the scientific literature published by Brazilian researchers shows that pregnant women infected by the novel coronavirus run a higher risk of developing pre-eclampsia, a pregnancy complication characterized by persistent high blood pressure, usually in the second half of pregnancy or shortly after delivery.
Disability Access Corporation, a subsidiary of PTS, Inc., announced today that Disability Access Consultants, Inc.(DAC), a wholly owned subsidiary of Disability Access Corporation reporting on a separate company basis, that as of September 30, 2009 third quarter unaudited revenues were approximately $441,000.
With an increasingly aging prison population, end-of-life care for inmates is becoming a more prominent issue, according to Penn State nursing researchers. End-of-life - EOL - care can be complicated, no matter who the patient is, but can be especially challenging for those behind bars.
Oncolytics Biotech Inc. announced today that enrollment has begun in a 2-Arm randomized Phase II study of carboplatin, paclitaxel plus REOLYSIN versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer.
› Verified 9 days ago